(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network!. Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






InMed Rockets with INM-901 as Potential Alzheimer's Game-Changer

  • October 24th, 2023
  • 725 views

Shares of InMed Pharmaceuticals Inc. (Nasdaq: INM) surged by over 100% in pre-market trading following the company's announcement that it has identified a promising lead candidate, INM-901, for the treatment of Alzheimer's disease, based on highly positive proof-of-concept study results.

InMed said that its cannabinoid analog INM-901 showed early potential in targeting various Alzheimer's-related pathways, including brain neuron protection and improved neuronal function. Preclinical studies also indicated positive trends in cognitive function, locomotor activity, anxiety-based behavior, and sound awareness compared to a placebo group.

The cannabinoid-focused drugmaker is now gearing up for advanced preclinical studies, including drug metabolism and pharmacokinetics, and taking steps toward pharmaceutical drug development.

$INM was trading a $1.58 in pre-market, up $1.00 (+172.41%)

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Tags

Social Shares

Post Your Comments

Want To Find Some News?

Recent Posts

News By Industries

Tags